According to the ADA guidelines, GLP-1 agonists are recommended for individuals with type DM, especially if the patient has or is at high risk of atherosclerotic cardiovascular disease (ASCVD) or has chronic kidney disease (CKD), especially if no albuminuria is present. Here, GCG is linked to chronic kidney disease.